XGEVA Drug Profile
✉ Email this page to a colleague
Summary for Tradename: XGEVA
High Confidence Patents: | 0 |
Applicants: | 1 |
BLAs: | 1 |
Pharmacology for XGEVA
Mechanism of Action | RANK Ligand Blocking Activity |
Established Pharmacologic Class | RANK Ligand Inhibitor |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- General brand-side disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for XGEVA Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for XGEVA Derived from Company Disclosures
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
---|---|---|---|---|---|---|---|
Amgen Inc. | XGEVA | denosumab | Injection | 125320 | ⤷ Sign Up | Company disclosures | |
Amgen Inc. | XGEVA | denosumab | Injection | 125320 | ⤷ Sign Up | 2016-12-23 | Company disclosures |
Amgen Inc. | XGEVA | denosumab | Injection | 125320 | ⤷ Sign Up | 2017-04-16 | Company disclosures |
Amgen Inc. | XGEVA | denosumab | Injection | 125320 | ⤷ Sign Up | 2021-06-26 | Company disclosures |
Amgen Inc. | XGEVA | denosumab | Injection | 125320 | ⤷ Sign Up | 2016-12-23 | Company disclosures |
Amgen Inc. | XGEVA | denosumab | Injection | 125320 | ⤷ Sign Up | 2016-12-23 | Company disclosures |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
3) Low Certainty: US Patents for XGEVA Derived from Patent Text Search
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
---|---|---|---|---|---|---|---|
Amgen Inc. | XGEVA | denosumab | Injection | 125320 | ⤷ Sign Up | 2039-02-26 | Patent claims search |
Amgen Inc. | XGEVA | denosumab | Injection | 125320 | ⤷ Sign Up | 2033-03-11 | Patent claims search |
Amgen Inc. | XGEVA | denosumab | Injection | 125320 | ⤷ Sign Up | 2030-10-06 | Patent claims search |
Amgen Inc. | XGEVA | denosumab | Injection | 125320 | ⤷ Sign Up | 2032-10-22 | Patent claims search |
Amgen Inc. | XGEVA | denosumab | Injection | 125320 | ⤷ Sign Up | 2034-07-17 | Patent claims search |
Amgen Inc. | XGEVA | denosumab | Injection | 125320 | ⤷ Sign Up | 2022-03-20 | Patent claims search |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
International Patents for XGEVA
Country | Patent Number | Estimated Expiration |
---|---|---|
Norway | 20190456 | ⤷ Sign Up |
Germany | 69939822 | ⤷ Sign Up |
Georgia, Republic of | P20033002 | ⤷ Sign Up |
Montenegro | 00232 | ⤷ Sign Up |
Japan | 2002514418 | ⤷ Sign Up |
Norway | 344842 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for XGEVA
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|
SPC/GB10/045 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: DENOSUMAB, IMMUNOGLOBULIN G2, ANTI-(HUMAN TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 11 (HUMAN OSTEOCLAST DIFFERENTIATION FACTOR)) (HUMAN MONOCLONAL AMG162 HEAVY CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL AMG162 LIGHT CHAIN, DIMER; REGISTERED: UK EU/1/10/618/001 20100526; UK EU/1/10/618/002 20100526; UK EU/1/10/618/003 20100526; UK EU/1/10/618/004 20100526 |
2010C/038 | Belgium | ⤷ Sign Up | PRODUCT NAME: DENOSUMAB; AUTHORISATION NUMBER AND DATE: EU/1/10/618/001 20100528 |
132010901893989 | Italy | ⤷ Sign Up | PRODUCT NAME: DENOSUMAB(PROLIA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/10/618/001-004, 20100526 |
132010901893988 | Italy | ⤷ Sign Up | PRODUCT NAME: DENOSUMAB(PROLIA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/10/618/001-004, 20100526 |
45/2010 | Austria | ⤷ Sign Up | PRODUCT NAME: DENOSUMAB; REGISTRATION NO/DATE: EU/1/10/618/001-004 MITTEILUNG 20100528 |
2010/036 | Ireland | ⤷ Sign Up | PRODUCT NAME: DENOSUMAB (PROLIA ); NAT REGISTRATION NO/DATE: EU/1/10/618/001 20100526; FIRST REGISTRATION NO/DATE: EU/1/10/618/002 26/05/2010 IRELAND EU/1/10/618/003 26/05/2010 IRELAND EU/1/10/618/004 26/05/2010 IRELAND EU/1/10/618/001 26/05/2010 IRELAND EU/1/10/618/002 26/05/2010 IRELAND EU/1/10/618/003 26/05/2010 IRELAND EU/1/10/618/004 20100526 |
>Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |